

HER2 Inhibitors Market Trends Involve Strategic Acquisitions And Collaborations

The Business Research Company's HER2 Inhibitors Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, May 13, 2021 /EINPresswire.com/ --

Biotechnology companies are focusing on acquiring or partnering with biopharmaceutical companies to develop and promote the HER-2 inhibitors market. As per [HER2 inhibitors market](#) analysis, there have been several partnerships in recent


years which help these companies to increase their HER-2 inhibitors portfolio, enhance their revenues and share the costs. For instance, in June 2020, Alphamab Oncology, a biotechnology company, collaborated with Sanofi, a pharmaceutical company, to investigate KN026 in combination with other drugs for the treatment of HER2 breast cancer. KN026 is a HER2 inhibitor developed by Alphamab Oncology. In 2019, Daiichi Sankyo announced its collaboration with AstraZeneca for development and commercialization collaboration for Daiichi Sankyo's HER2 targeting antibody drug conjugate.

In March 2018, Seattle Genetics announced its decision to acquire Cascadian Therapeutics for \$614 million. Cascadian Therapeutics is a US-based company that had developed an oral tyrosine kinase inhibitor, which is pivotal in mid-stage tests for advanced HER2 breast cancers. It is also slated for tests in other HER2 cancers such as colon cancer. The acquisition is expected to positively impact Seattle Genetics' product portfolio and boost its late-stage cancer drug pipeline.

Major players in the HER2 inhibitors market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Boehringer-Ingelheim, Mylan, Biocon.

Read More On The Global HER2 Inhibitors Market Report:

<https://www.thebusinessresearchcompany.com/report/her2-inhibitors-market-global-report-2020-30-covid-19-growth-and-change>



The global HER2 inhibitors market is expected to grow from \$5.98 billion in 2020 to \$6.4 billion in 2021 at a compound annual growth rate (CAGR) of 7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The HER2 inhibitors breast cancer drugs market size is expected to reach \$9.31 billion in 2025 at a CAGR of 10%. The countries with HER2 inhibitors market shares covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The HER2 inhibitor market covered in this report is segmented by treatment into monotherapy, combination therapy; by application into squamous cell carcinoma, adenocarcinoma, large cell carcinoma, breast cancer, others; by end user into hospitals, clinics, others.

[HER2 Inhibitors Global Market Report 2021](#): COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides HER2 inhibitors market overview, forecast HER2 inhibitors market size and growth for the whole market, HER2 inhibitors market segments, and geographies, HER2 inhibitors market trends, HER2 inhibitors market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global HER2 Inhibitors Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3396&type=smp>

Here Is A List Of Similar Reports By The Business Research Company:

Breast Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

<https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report>

Checkpoint Inhibitors Global Market Report 2021: COVID-19 Growth And Change To 2030

<https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitors-global-market-report-2020-30-covid-19-growth-and-change>

Interleukin Inhibitors Global Market Report 2021: COVID-19 Growth And Change To 2030

<https://www.thebusinessresearchcompany.com/report/interleukin-inhibitors-global-market-report-2020-30-covid-19-growth-and-change>

Immunosuppressants Global Market Report 2021: COVID-19 Growth And Change To 2030

<https://www.thebusinessresearchcompany.com/report/immunosuppressants-global-market-report-2020-30-covid-19-growth-and-change>

Interested to know more about [The Business Research Company?](#)

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/541025181>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.